Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of SHR7280 tablets in women with uterine fibroids and heavy menstrual bleeding
CTR20221516Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SHR7280 in Fibromyoma (LM), sponsored by Hengrui Therapeutics. Started Dec 2022; status: active.
02
Drugs
SHR7280
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on CTR20221516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221516.